Upregulated expression of MMP family genes is associated with poor survival in patients with esophageal squamous cell carcinoma via regulation of proliferation and epithelial‑mesenchymal transition.


Journal

Oncology reports
ISSN: 1791-2431
Titre abrégé: Oncol Rep
Pays: Greece
ID NLM: 9422756

Informations de publication

Date de publication:
07 2020
Historique:
received: 13 10 2019
accepted: 13 03 2020
entrez: 7 7 2020
pubmed: 7 7 2020
medline: 10 3 2021
Statut: ppublish

Résumé

Matrix metalloproteinases (MMPs) are involved in the cleavage of several components of the extracellular matrix and serve important roles in tumor growth, metastasis and invasion. Previous studies have focused on the expression of one or several MMPs in esophageal squamous cell carcinoma (ESCC); however, in the present study, the transcriptomics of all 23 MMPs were systematically investigated with a focus on the prognostic value of the combination of MMPs. In this study, 8 overlapping differentially expressed genes of the MMP family were identified based on data obtained from Gene Expression Omnibus and The Cancer Genome Atlas. The prognostic value of these MMPs were investigated; the receiver operating characteristic curves, survival curves and nomograms showed that the combination of 6 selected MMPs possessed a good predictive ability, which was more accurate than the prediction model based on Tumor‑Node‑Metastasis stage. Gene set enrichment analysis and gene co‑expression analysis were performed to investigate the potential mechanism of action of MMPs in ESCC. The MMP family was associated with several signaling pathways, such as epithelial‑mesenchymal transition (EMT), Notch, TGF‑β, mTOR and P53. Cell Counting Kit‑8, colony formation, wound healing assays and western blotting were used to determine the effect of BB‑94, a pan‑MMP inhibitor, on proliferation and migration of ESCC cells. BB‑94 treatment decreased ESCC cell growth, migration and EMT. Therefore, MMPs may serve both as diagnostic and prognostic biomarkers of ESCC, and MMP inhibition may be a promising preventive and therapeutic strategy for patients with ESCC.

Identifiants

pubmed: 32627007
doi: 10.3892/or.2020.7606
pmc: PMC7251684
doi:

Substances chimiques

Matrix Metalloproteinases EC 3.4.24.-

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

29-42

Références

Braz J Med Biol Res. 2012 Jan;45(1):86-92
pubmed: 22086466
Acta Radiol. 2006 Apr;47(3):303-10
pubmed: 16613313
Dis Esophagus. 2009;22(8):664-7
pubmed: 19191857
J Biol Chem. 2014 Mar 21;289(12):8442-9
pubmed: 24492617
Ann Oncol. 1999 May;10(5):589-91
pubmed: 10416010
Clin Cancer Res. 2011 May 1;17(9):2955-66
pubmed: 21385931
Hepatol Res. 2009 Feb;39(2):177-86
pubmed: 19208038
J Am Coll Surg. 2003 Apr;196(4):573-8
pubmed: 12691934
Oncol Lett. 2019 Aug;18(2):1199-1206
pubmed: 31423180
Sci Rep. 2015 Aug 21;5:13413
pubmed: 26292924
BMC Genomics. 2015 Sep 26;16(1):732
pubmed: 26409826
Gut. 2014 Nov;63(11):1700-10
pubmed: 24522499
Onco Targets Ther. 2018 Jul 24;11:4301-4314
pubmed: 30100736
J Thorac Dis. 2018 Aug;10(Suppl 22):S2671-S2681
pubmed: 30345104
Cancer Metastasis Rev. 2006 Mar;25(1):9-34
pubmed: 16680569
Thorac Cancer. 2016 Mar;7(2):232-7
pubmed: 27042227
Clin Exp Metastasis. 2008;25(6):593-600
pubmed: 18286378
Surgery. 2003 May;133(5):486-94
pubmed: 12773976
BMC Infect Dis. 2014 Dec 31;14:726
pubmed: 25551808
J Cell Physiol. 2019 Jul;234(7):11023-11036
pubmed: 30633343
Mol Cell Biol. 2013 Dec;33(24):4985-95
pubmed: 24126059
Oncogene. 2020 Jan;39(1):204-218
pubmed: 31467432
Science. 2002 Mar 29;295(5564):2387-92
pubmed: 11923519
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
J Biol Chem. 2000 Jul 7;275(27):20540-4
pubmed: 10801841
J Cancer Res Clin Oncol. 2018 Mar;144(3):439-447
pubmed: 29299749
Oncol Lett. 2017 Nov;14(5):5865-5870
pubmed: 29113219
Sci Rep. 2016 Feb 24;6:21903
pubmed: 26906973
Nat Rev Mol Cell Biol. 2007 Mar;8(3):221-33
pubmed: 17318226
Int J Oncol. 2016 Dec;49(6):2255-2264
pubmed: 27779648
Genome Res. 2003 Nov;13(11):2498-504
pubmed: 14597658
Acta Biochim Pol. 2005;52(2):329-37
pubmed: 15990918
Sci Rep. 2019 Aug 12;9(1):11677
pubmed: 31406154
Best Pract Res Clin Gastroenterol. 2007;21(6):921-45
pubmed: 18070696
Cold Spring Harb Perspect Biol. 2011 Jan 01;3(1):a004978
pubmed: 21421911
Cancer Lett. 2016 Jul 10;377(1):97-104
pubmed: 27130665
J Exp Clin Cancer Res. 2015 Feb 12;34:16
pubmed: 25887589
Bioinformatics. 2010 Jan 1;26(1):139-40
pubmed: 19910308
Onco Targets Ther. 2018 Mar 15;11:1457-1474
pubmed: 29588600
Methods Mol Biol. 2014;1150:153-60
pubmed: 24743996
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Cancer Discov. 2014 Apr;4(4):405-14
pubmed: 24658082
Breast Cancer Res. 2000;2(4):252-7
pubmed: 11250717
Cancer Res. 1994 Sep 1;54(17):4726-8
pubmed: 8062271
Am J Gastroenterol. 2005 Aug;100(8):1835-43
pubmed: 16086722
J Enzyme Inhib Med Chem. 2016;31(sup1):177-183
pubmed: 27028474
Lancet. 2013 Feb 2;381(9864):400-12
pubmed: 23374478
Chin J Cancer Res. 2013 Dec;25(6):637-45
pubmed: 24385690
J Clin Oncol. 2008 Mar 10;26(8):1364-70
pubmed: 18323559
N Engl J Med. 2015 Apr 9;372(15):1472-3
pubmed: 25853757
Pharmacol Ther. 2014 Feb;141(2):140-9
pubmed: 24076266
Int J Oncol. 2014 Jul;45(1):393-400
pubmed: 24819550
Sci Rep. 2016 Feb 26;6:22179
pubmed: 26916665
Clin Chim Acta. 2008 Mar;389(1-2):61-6
pubmed: 18155162
BMC Bioinformatics. 2008 Dec 29;9:559
pubmed: 19114008
Pathol Res Pract. 2017 Dec;213(12):1519-1522
pubmed: 29033183
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Onco Targets Ther. 2017 Jun 02;10:2837-2847
pubmed: 28652766
Cancers (Basel). 2019 Jun 21;11(6):
pubmed: 31234340
BMC Cancer. 2019 Jun 14;19(1):581
pubmed: 31200666
J Cell Physiol. 2020 Feb;235(2):1624-1636
pubmed: 31309563

Auteurs

Guifeng Xu (G)

School of Pharmaceutical Sciences, Shenzhen University Health Science Center, Shenzhen, Guangdong 518060, P.R. China.

Ling Ou (L)

Department of Pharmacy, The Second Clinical Medical College (Shenzhen People's Hospital), Jinan University, Shenzhen 518020, P.R. China.

Ying Liu (Y)

Department of Pharmacy, The Second Clinical Medical College (Shenzhen People's Hospital), Jinan University, Shenzhen 518020, P.R. China.

Xiao Wang (X)

Department of Pharmacy, The Second Clinical Medical College (Shenzhen People's Hospital), Jinan University, Shenzhen 518020, P.R. China.

Kaisheng Liu (K)

Department of Pharmacy, The Second Clinical Medical College (Shenzhen People's Hospital), Jinan University, Shenzhen 518020, P.R. China.

Jieling Li (J)

School of Pharmaceutical Sciences, Shenzhen University Health Science Center, Shenzhen, Guangdong 518060, P.R. China.

Junjun Li (J)

State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Taipa, Macau 999078, P.R. China.

Shaoqi Wang (S)

Department of Oncology, Hubei Provincial Corps Hospital, Chinese People Armed Police Forces, Wuhan, Hubei 430061, P.R. China.

Dane Huang (D)

Guangdong Province Engineering Technology Research Institute of Traditional Chinese Medicine, Guangdong Provincial Key Laboratory of Research and Development in Traditional Chinese Medicine, Guangzhou, Guangdong 510095, P.R. China.

Kai Zheng (K)

School of Pharmaceutical Sciences, Shenzhen University Health Science Center, Shenzhen, Guangdong 518060, P.R. China.

Shaoxiang Wang (S)

School of Pharmaceutical Sciences, Shenzhen University Health Science Center, Shenzhen, Guangdong 518060, P.R. China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH